Drug
S-adenosylmethionine
S-adenosylmethionine is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
unknown
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
NCT05701553
completedphase_1
Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine
NCT00473200
completedphase_3
Effects of SAMe in Patients With Alcoholic Liver Disease
NCT00573313
completedphase_3
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
NCT00108589
Clinical Trials (4)
Showing 4 of 4 trials
NCT05701553
Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma
NCT00473200Phase 1
Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine
NCT00573313Phase 3
Effects of SAMe in Patients With Alcoholic Liver Disease
NCT00108589Phase 3
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4